Name | GB1107 |
---|
Description | GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model[1]. |
---|---|
Related Catalog | |
Target |
Kd: 37 nM (human Gal-3)[1]. |
In Vitro | Treatment with GB1107 (0-1 μM) increases tumor M1 macrophage polarization and CD8+ T cell infiltration in LLC cells by flow cytometric analysis. GB1107 potentiates the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFN-γ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules[1]. |
In Vivo | GB1107 (10 mg/kg, p.o., once daily from day 18-30 post implantation) treatment results in significantly reduced tumor growth and final tumor weights[1]. Animal Model: CD-1 nude female mice received 3x106 human lung adenocarcinoma cells (A549)[1]. Dosage: 10 mg/kg Administration: Oral once daily from day 18-30 post implantation. Result: Resulted in significantly reduced tumor growth and final tumor weights. |
References |
Molecular Formula | C20H16Cl2F3N3O4S |
---|---|
Molecular Weight | 522.32 |
Storage condition | -20°C |